ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Neurotrophic keratopathy patients after minimally invasive corneal neurotization treated with RhNGF eyedrops: a case series.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo assess whether recombinant human nerve growth factor (rhNGF) eye drops used in neurotrophic keratopathy (NK) patients after minimally invasive corneal neurotization (MICN) surgery can accelerate the process of reinnervation and shorten the patient’s postoperative recovery time.
methodsThe authors highlight 5 cases that have all undergone MICN and been treated with rhNGF eyedrops. Cases include: 4 cases that have been over 1 year since MICN and 1 case that were 6 months after MICN. Three patients after MICN treated with conventional medication were enrolled as controls. The evaluation indicators include corneal sensation, sub-basal corneal nerve density, tear secretion and tear break-up time, best-corrected visual acuity, corneal epithelium condition and clinical symptoms. All rhNGF group patients were treated with rhNGF eyedrops for 4 weeks.
resultsAfter 4 weeks of rhNGF drops treatment in 5 patients, corneal sensation was significantly improved, corneal nerve fiber length, nerve branch density increased, and corneal nerve trunk diameter improved. At the same time, corneal damage was reduced and best-corrected visual acuity was improved. Both corneal sensation and nerve density, as well as corneal morphology, recovered faster compared to postoperative patients who applied conventional medications.
conclusionsrhNGF eyedrops may speed up the healing process of corneal neurotization and help improve corneal sensation. Meanwhile, the time point of applying rhNGF eyedrops may depend on the baseline corneal nerve condition.
Indexed as
Identifiers
41572031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.